SCM
IRWD icon

Segantii Capital Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Segantii Capital Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3,463
Closed -$49K – 162
2017
Q1 		$49K Buy
+3,463
New +$47.3K 0.01% 280

Other funds holding IRWD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Segantii Capital Management's IRWD Position: Q2 2017 in Review

Segantii Capital Management sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2017, closing a stake of 3,463 shares — an estimated $49K sold.

Segantii Capital Management first reported a position in IRWD in Q1 2017 and held it in 1 quarter. The position peaked at $49K in Q1 2017. 167 funds tracked by Wall St. Rank hold IRWD as of Q2 2017.

  • Segantii Capital Management reported no remaining Ironwood Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Segantii Capital Management sold 3,463 Ironwood Pharmaceuticals shares in Q2 2017, an estimated $49K.
  • Segantii Capital Management first reported a position in Ironwood Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Segantii Capital Management's Ironwood Pharmaceuticals position peaked at $49K in Q1 2017.
  • 167 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2017.

Based on Segantii Capital Management's 13F filing for Q2 2017, filed 2 Aug 2017.